Bioequivalence Study of Favipiravir From Flupirava 200 mg Tablet (European Egyptian Pharmaceutical Industries , Egypt) Versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan)

NCT04478448 | Completed Phase 1

• 1 other identifier: GRC/1/20/869
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Favipiravir from Flupirava 200 mg tablet (European Egyptian Pharmaceutical Industries, Egypt) versus Avigan 200 mg Tablets (Man. by Toyama Chemical Co., Ltd Japan) in Healthy Human Volunteers Under Fasting Condition.

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

• Cmax

  Maximal measured plasma concentration

  Up to 36 hours post dose in each treatment period

Secondary Outcomes (1)

• Time of the maximum plasma concentration (Tmax)

  Up to 36 hours post dose in each treatment period

Study Arms (2)

T test

EXPERIMENTAL

Test drug (Flupirava) 1 tablet contains 200 mg Favipiravir

Drug: Flupirava

B reference

ACTIVE COMPARATOR

Reference drug (Avigan) 1 tablet contains 200 mg Favipiravir

Drug: Avigan

Interventions

Flupirava DRUG

1 tablet contains 200 mg Favipiravir

Also known as: Avigan

T test

Avigan DRUG

1 tablet contains 200 mg Favipiravir

B reference

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• \. Healthy male or female, age 18 to 55 years, inclusive. 2. Body weight within 15% of normal range according to the accepted normal values for body mass index (BMI).
• \. Medical demographics without evidence of clinically significant deviation from normal medical condition.
• \. Results of clinical laboratory test are within the normal range or with a deviation that is not considered clinically significant by principal investigator.
• \. Subject does not have allergy to the drugs under investigation. 6. Females should be on a suitable birth control method.

You may not qualify if:

• \. Subjects with known allergy to the products tested. 2. Subjects whose values of BMI were outside the accepted normal ranges. 3. Female subjects who were pregnant or nursing. 4. Medical demographics with evidence of clinically significant deviation from normal medical condition.
• \. Results of laboratory tests which are clinically significant. 6. Acute infection within one week preceding first study drug administration. 7. History of drug or alcohol abuse. 8. Subject does not agree not to take any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study.
• \. Subject is on a special diet (for example subject is vegetarian). 10. Subject does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period.
• \. Subject does not agree not to consume any beverages or foods containing grapefruit 7 days prior to first study drug administration until the end of the study.
• \. Subject has a history of severe diseases which have direct impact on the study.
• \. Participation in a bioequivalence study or in a clinical study within the last 6 weeks before first study drug administration.
• \. Subject intends to be hospitalized within 3 months after first study drug administration.
• \. Subjects who, through completion of this study, would have donated more than 500 ml of blood in 7 days, or 750 ml of blood in 30 days, 1000 ml in 90 days, 1250 ml in 120 days, 1500 ml in 180 days, 2000 ml in 270 days, 2500 ml of blood in 1 year.

Sponsors & Collaborators

• Genuine Research Center, Egypt: lead
• European Egyptian Pharmaceutical Industries: collaborator

Study Sites (1)

Genuine Research Center GRC

Cairo, 11757, Egypt

Location

Related Publications (3)

• Chow SC, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):155-69. doi: 10.1023/a:1011503032353.

  PMID: 11381568 BACKGROUND

• Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1991 Jan;29(1):1-8.

  PMID: 2004861 BACKGROUND

• Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80. doi: 10.1007/BF01068419.

  PMID: 3450848 BACKGROUND

MeSH Terms

Interventions

favipiravir

Study Officials

• Ahmed Elshafeey, Ph.D. Pharma

  Genuine Research Center

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 16, 2020
• First Posted: July 20, 2020
• Study Start: August 13, 2020
• Primary Completion: August 20, 2020
• Study Completion: August 26, 2020
• Last Updated: September 2, 2020

Record last verified: 2020-08

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)